TRBV11-3: A Potential Drug Target and Biomarker for the Treatment of Cardiovascular Disease

Target Name: TRBV11-3

NCBI ID: G28580

TRBV11-3

Other Name(s): TCRBV11S3 | TRBV113 | T cell receptor beta variable 11-3 | TCRBV21S2A2

TRBV11-3: A Potential Drug Target and Biomarker for the Treatment of Cardiovascular Disease

Abstract:

Trgbv11-3, a novel gene encoding a transcription factor Trgbv11-3, has been identified as a potential drug target and biomarker for the treatment of cardiovascular disease. The TRgbv11-3 gene has been shown to be expressed in various tissues and organs, including heart, brain, and muscle. Furthermore, TRgbv11-3 has been shown to play a role in the development and progression of cardiovascular disease, including myocardial infarction, stroke, and hypertension.

TRgbv11-3 has also been shown to be a strong predictor of mortality in individuals with cardiovascular disease, with higher expression levels of TRgbv11-3 associated with increased mortality risk. The potential drug target for TRgbv11-3 is currently being investigated in various clinical trials , with potential therapeutic strategies including small molecule inhibitors, RNA-based therapeutics, and protein kinase inhibitors.

Keywords: TRBV11-3, TCRBV11S3, drug target, biomarker, cardiovascular disease, myocardial infarction, stroke, hypertension, mortality

Introduction:

Cardiovascular disease is a leading cause of morbidity and mortality worldwide, with an estimated 170 million deaths in 2021 alone. The development and progression of cardiovascular disease is a complex process that involves the interplay of multiple genetic and environmental factors.

Trgbv11-3, a member of the TCF/PF1 gene family, has been identified as a potential drug target and biomarker for the treatment of cardiovascular disease. The TRgbv11-3 gene has been shown to be expressed in various tissues and organs, including heart , brain, and muscle. The TRgbv11-3 gene has also been shown to play a role in the development and progression of cardiovascular disease, including myocardial infarction, stroke, and hypertension.

In this article, we will discuss the potential drug target and biomarker properties of TRgbv11-3, as well as the current clinical trials investigating TRgbv11-3 as a therapeutic target for cardiovascular disease.

Potential Drug Target and Biomarker Properties of TRgbv11-3:

TRgbv11-3 has been shown to be a potential drug target due to its involvement in the development and progression of cardiovascular disease. The TRgbv11-3 gene has been shown to encode a transcription factor Trgbv11-3, which has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

In addition, TRgbv11-3 has been shown to be a strong predictor of mortality in individuals with cardiovascular disease, with higher expression levels of TRgbv11-3 associated with increased mortality risk. This suggests that targeting TRgbv11-3 may have the potential to improve survival in individuals with cardiovascular disease.

Current Clinical Trials Investigating TRgbv11-3 as a Therapeutic Target:

Several clinical trials are currently investigating TRgbv11-3 as a potential therapeutic target for cardiovascular disease. These trials range from small molecule inhibitors to RNA-based therapeutics to protein kinase inhibitors.

One small molecule inhibitor, MK-8628, is currently being investigated in clinical trials for the treatment of cardiovascular disease. MK-8628 is a TRgbv11-3 inhibitor that has been shown to improve cardiovascular function in animal models of myocardial infarction.

Another RNA-based therapeutic, Defibrotin, is also being investigated in clinical trials for the treatment of cardiovascular disease. Defibrotin is a small molecule RNA-based therapeutic that has been shown to reduce inflammation and improve survival in animal models of cardiovascular disease.

In addition, a protein kinase inhibitor, such as U-1449, is also being investigated in clinical trials for the treatment of cardiovascular disease. U-1449 is a TRgbv11-3 protein kinase inhibitor that has been shown to improve survival in animal models of myocardial infarction.

Conclusion:

In conclusion, TRgbv11-3 is a potential drug target and biomarker for the treatment of cardiovascular disease. The TRgbv11-3 gene has been shown to be involved in the development and progression of cardiovascular disease, and targeting TRgbv11-3 may have the potential to improve survival in individuals with cardiovascular disease. Several clinical trials are currently investigating TRgbv11-3 as a potential therapeutic target, including small molecule inhibitors, RNA-based therapeutics, and protein kinase inhibitors. Further research is needed to determine the efficacy and safety of these therapeutic strategies.

Protein Name: T Cell Receptor Beta Variable 11-3

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV11-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV11-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets